CTMX News and Press, CytomX Therapeutics Inc.

2026-02-25 09:16:35 ET More on small cap stocks This Is Not A Normal Rotation - It's A Regime Change U.S. Treasury Debt-To-GDP Ratio Rises To 122% In Q4, Highest Since Covid Spike S&P 500: Supreme Court Ruling On Tariffs Increases Market Volatility After ...

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: B...

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase o...

2026-01-14 14:36:02 ET CytomX Therapeutics, Inc. (CTMX) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthc...

- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 ...

2025-12-24 07:00:30 ET Overview My last look at CytomX Therapeutics, Inc. ( CTMX ) was in October and followed preliminary data for its EpCAM-targeted, topo-1 Probody-ADC, CX-2051.... Read the full article on Seeking Alpha For further details see: CytomX Ther...

2025-12-15 01:46:13 ET ... Read the full article on Seeking Alpha For further details see: CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling

2025-12-04 08:00:00 ET Although the S&P ended the month about where it started, there was significant volatility in between, including a sharp drop and equally sharp rebound. Given this volatility, are there any compelling investment ideas out there that may have flown under you...

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December. 8 th A...

2025-11-18 09:32:02 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: CytomX Therapeutics: Leaning Into The Hype, But What's Next?